RCMI Coordinating Center (RCMI CC) Header Logo

Connection

John Piletz to Binding Sites

This is a "connection" page, showing publications John Piletz has written about Binding Sites.
Connection Strength

0.459
  1. Zhu H, Halaris A, Piletz JE. Atypical [(3)H]clonidine binding sites in human caudate and platelets on cryostat-cut sections. Ann N Y Acad Sci. 2003 Dec; 1009:296-301.
    View in: PubMed
    Score: 0.051
  2. Piletz JE, Ordway GA, Rajkowska G, Zhu H, Klimek V, Swilley S, Duncan BJ, May W, Halaris AE. Differential expression of alpha2-adrenoceptor vs. imidazoline binding sites in postmortem orbitofrontal cortex and amygdala of depressed subjects. J Psychiatr Res. 2003 Sep-Oct; 37(5):399-409.
    View in: PubMed
    Score: 0.050
  3. Halaris A, Zhu H, Ali J, Nasrallah A, Lindsay De Vane C, Piletz JE. Down-regulation of platelet imidazoline-1-binding sites after bupropion treatment. Int J Neuropsychopharmacol. 2002 Mar; 5(1):37-46.
    View in: PubMed
    Score: 0.045
  4. Piletz JE, Ordway GA, Zhu H, Duncan BJ, Halaris A. Autoradiographic comparison of [3H]-clonidine binding to non-adrenergic sites and alpha(2)-adrenergic receptors in human brain. Neuropsychopharmacology. 2000 Dec; 23(6):697-708.
    View in: PubMed
    Score: 0.041
  5. Piletz JE, Halbreich U. Imidazoline and alpha(2a)-adrenoceptor binding sites in postmenopausal women before and after estrogen replacement therapy. Biol Psychiatry. 2000 Nov 01; 48(9):932-9.
    View in: PubMed
    Score: 0.041
  6. Zhu H, Halaris A, Piletz JE. Chronic imipramine treatment downregulates IR1-imidazoline receptors in rat brainstem. Life Sci. 1997; 61(19):1973-83.
    View in: PubMed
    Score: 0.031
  7. Piletz JE, Zhu H, Chikkala DN. Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov; 279(2):694-702.
    View in: PubMed
    Score: 0.031
  8. Piletz JE, Halaris A, Nelson J, Qu Y, Bari M. Platelet I1-imidazoline binding sites are elevated in depression but not generalized anxiety disorder. J Psychiatr Res. 1996 May-Jun; 30(3):147-68.
    View in: PubMed
    Score: 0.030
  9. Piletz JE, Halaris AE, Chikkala D, Qu Y. Platelet I1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients. J Psychiatr Res. 1996 May-Jun; 30(3):169-84.
    View in: PubMed
    Score: 0.030
  10. Piletz JE, Chikkala DN, Ernsberger P. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. J Pharmacol Exp Ther. 1995 Feb; 272(2):581-7.
    View in: PubMed
    Score: 0.028
  11. Piletz JE, Sletten K. Nonadrenergic imidazoline binding sites on human platelets. J Pharmacol Exp Ther. 1993 Dec; 267(3):1493-502.
    View in: PubMed
    Score: 0.025
  12. Piletz JE, Andorn AC, Unnerstall JR, Halaris A. Binding of [3H]-p-aminoclonidine to alpha 2-adrenoceptor states plus a non-adrenergic site on human platelet plasma membranes. Biochem Pharmacol. 1991 Jul 15; 42(3):569-84.
    View in: PubMed
    Score: 0.022
  13. Piletz JE, Andorn AC, Halaris A. 3H-clonidine and 3H-yohimbine binding to glass fiber filters: implications for studies with platelet membranes. Psychopharmacology (Berl). 1986; 89(3):370-7.
    View in: PubMed
    Score: 0.015
  14. Sano H, Liu SC, Lane WS, Piletz JE, Lienhard GE. Insulin receptor substrate 4 associates with the protein IRAS. J Biol Chem. 2002 May 31; 277(22):19439-47.
    View in: PubMed
    Score: 0.011
  15. Suzuki T, Yamamoto T, Hori T, Baba A, Shiraishi H, Ito T, Piletz JE, Ho IK. Autoradiographic study on the pharmacological characteristics of [3H]3-OH-PCP binding sites in rat brain. Eur J Pharmacol. 1996 Aug 29; 310(2-3):243-55.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support